ASX RELEASE 22 October 2026 Further Obsidian Note Redemption Paradigm Biopharmaceuticals Limited (Administrators Appointed) (ASX: PAR) ("Paradigm" or "the Company") advises that, following discussions with Obsidian Global GP, LLC ("Obsidian"), the parties have agreed to the redemption and...
Further Agreed Convertible Note Redemption
Filed with ASX · · 1 page · English
Release
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Notification of cessation of securities - PAR
- PPS Shows Significant Pain Benefit in Rest of World Analysis
- Expiry of PAROB Listed Options
- Update on Data Review and Convertible note redemption
- Continuation of Suspension from Quotation
Later from Paradigm Biopharmaceuticals
- Extension of Convening Period
- Deferral of AGM and Financial Reporting Obligations
- Convening Period Extended to 27 January 2027
- September 2026 Quarterly Activities Report & Appendix 4C
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals